Analysts have provided the following ratings for Biomarin Pharmaceutical BMRN within the last quarter:

These 15 analysts have an average price target of $118.2 versus the current price of Biomarin Pharmaceutical at $85.165, implying upside.

Below is a summary of how these 15 analysts rated Biomarin Pharmaceutical over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average represents a 9.08% decrease from the previous average price target of $130.00.

Stay up to date on Biomarin Pharmaceutical analyst ratings.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.